<DOC>
	<DOC>NCT02687867</DOC>
	<brief_summary>To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.</brief_summary>
	<brief_title>Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Nonvalvular atrial fibrillation will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD9 427.31 (International Classification of Disease, Ninth Revision, Clinical Modification) as the diagnosis code at any time in the patient's data history prior to inclusion Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics CHA2DS2Vasc (Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 6574 years; Sc: Sex category ) score â‰¥2 during the 180 days prior to index dabigatran use baseline period Patients &lt;18 years of age Patients with valvular Atrial fibrillation Pregnancy Malignant cancers Transient cause of Atrial fibrillation Patients with Venous thromboembolism (pulmonary embolism or Deep Vein Thrombosis) Patients with major surgery defined as hip or knee replacement Prescriptions of Oral anticoagulants (OACs) {apixaban, warfarin, dabigatran, rivaroxaban} before index date Prescription of more than one OAC on the index date Patient with any of the events defined in the composite endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
	<keyword>Prevention</keyword>
	<keyword>Stroke</keyword>
</DOC>